follicular

Cladribine (2CdA), an adenosine deaminase inhibitor, is utilized in the treatment of lymphoproliferative diseases.

Human Follicular Gonadotropin Releasing Peptide (hF-GRP) is a hormonal peptide that, in vitro, can induce the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1] [2].

Tazemetostat (EPZ6438) is a histone methyltransferase EZH2 inhibitor (IC50=11 nM) that is orally active, selective, and SAM-competitive. Tazemetostat exhibits antitumor activity and may be used for the treatment of epithelioid sarcoma/follicular lymphoma.

Pregnant mare serum gonadotropin (PMSG) functions as a gonadotropin that enhances follicular development and ovulation in animals. This compound operates by modulating blood hormones, gonadotropins, and cytoplasmic estradiol receptors in the anterior pituitary and hypothalamus. Commonly employed in livestock to boost reproductive efficiency, PMSG is also valuable for research focused on estrous cycle regulation.

FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor, exhibiting an IC50 of 4.5 nM for the Bcl-2/BAK interaction. It effectively suppresses tumor growth in mouse models of follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenografts without causing significant weight loss. FCN-338 demonstrates broad-spectrum anticancer activity, making it suitable for treating FL, chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), AML, and ALL.

1. Coixol (MBOA) acts as a central muscle relaxant with an anti-convulsant effect. 2. Coixol interacts with the pituitary to stimulate reproduction in voles. 3. Coixol has the ability to interact with FSH to stimulate follicular development and increase ovulation. 4. Coixol can regulate gene expression, production and secretion of mucin, by directly acting on airway epithelial cells.

Kisspeptin-54 is a peptide ligand of the orphan G protein-coupled receptor GPR54 (Kis = 1.81 and 1.45 nM for rat and human receptors, respectively).1 It is a 54 amino acid peptide encoded by the metastasis suppressor gene KISS-1. Kisspeptin-54 induces calcium mobilization in CHO-K1 cells expressing rat and human receptors (EC50s = 1.39 and 5.47 nM, respectively). It also induces arachidonic acid release in CHO cells expressing rat and human GPR54 in a concentration-dependent manner. Kisspeptin-54 (10-1,000 nM) inhibits insulin secretion from isolated mouse pancreatic β-cells in the presence of 2.8 mM, but not 11.1 mM, glucose.2 Kisspeptin-54 (1-5 nmol, i.c.v.) increases serum levels of luteinizing hormone (LH) and follicular stimulating hormone (FSH) in mice, an effect which is reversed by the gonadotropin releasing hormone (GNRH) antagonist acycline.3References1. Kotani, M., Detheux, M., Vandenbogaerde, A.L., et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J. Biol. Chem. 276(37), 34631-34636 (2001).2. Vikman, J., and Ahrén, B. Inhibitory effect of kisspeptins on insulin secretion from isolated mouse islets. Diabetes Obes. Metab. 11(Suppl 4), 197-201 (2009).3. Gottsch, M.L., Cunningham, M.J., Smith, J.T., et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology 145(9), 4073-4077 (2004). Kisspeptin-54 is a peptide ligand of the orphan G protein-coupled receptor GPR54 (Kis = 1.81 and 1.45 nM for rat and human receptors, respectively).1 It is a 54 amino acid peptide encoded by the metastasis suppressor gene KISS-1. Kisspeptin-54 induces calcium mobilization in CHO-K1 cells expressing rat and human receptors (EC50s = 1.39 and 5.47 nM, respectively). It also induces arachidonic acid release in CHO cells expressing rat and human GPR54 in a concentration-dependent manner. Kisspeptin-54 (10-1,000 nM) inhibits insulin secretion from isolated mouse pancreatic β-cells in the presence of 2.8 mM, but not 11.1 mM, glucose.2 Kisspeptin-54 (1-5 nmol, i.c.v.) increases serum levels of luteinizing hormone (LH) and follicular stimulating hormone (FSH) in mice, an effect which is reversed by the gonadotropin releasing hormone (GNRH) antagonist acycline.3 References1. Kotani, M., Detheux, M., Vandenbogaerde, A.L., et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J. Biol. Chem. 276(37), 34631-34636 (2001).2. Vikman, J., and Ahrén, B. Inhibitory effect of kisspeptins on insulin secretion from isolated mouse islets. Diabetes Obes. Metab. 11(Suppl 4), 197-201 (2009).3. Gottsch, M.L., Cunningham, M.J., Smith, J.T., et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology 145(9), 4073-4077 (2004).

DM-01 is a potent and selective inhibitor of EZH2. DM-01 can be used to study diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and SNF5/INI-1/SMARCB1 gene-associated solid tumours.

Acyline is a novel GnRH antagonist found in animal studies to be a potent suppressor of circulating gonadotropin and testosterone (T) levels. Acyline inhibits basal and GnRH-stimulated serum testosterone concentrations in male dogs. Acyline prevented ovulation, but did not affect ovarian follicular development or gestational corpora lutea in the domestic cat. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men.

PI3K-IN-36 is a potent inhibitor of PI3K, suitable for research applications in follicular lymphoma (FL).

FSH receptor-binding inhibitor fragment (bi-10) is a potent antagonist that inhibits the binding of follicle-stimulating hormone (FSH) to its receptor (FSHR), modifying FSH activity at the receptor level. It suppresses ovulation and induces follicular atresia in mice. Furthermore, this compound holds potential for curbing ovarian cancer carcinogenesis by reducing the overexpression of FSHR and estrogen receptor beta (ERβ) in the ovaries [1].

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).

Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell killing by T-cells and natural killer cells, and enhancing the cytotoxicity of Rituximab.Urelumab has been used in the study of solid tumor-related diseases such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Urelumab can be used to study diseases associated with solid tumors such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Menotropin (Human Menopausal Gonadotropin) is a hormone discovered in the urine of postmenopausal women, possessing dual activity as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It promotes follicular growth and development, as well as the secretion of gonadal steroid hormones.

Oligopeptide-41 acetate is a synthetic, short-chain bioactive peptide sequence, typically formulated as an acetate salt to enhance stability and solubility, that has been reported to possess hair growth-promoting effects by potentially stimulating follicular cells and is consequently used as a functional cosmetic ingredient in topical formulations.

Pidilizumab (CT-011) is a humanized monoclonal antibody that modulates anti-tumor immune responses by targeting the PD-1 receptor and the Notch ligand DLL1. It enhances the activity of T cells and natural killer (NK) cells, demonstrating significant clinical potential in the study of hematologic malignancies, particularly follicular lymphoma.

Palmitoyl Tetrapeptide-20 (PTP20) is a bioactive peptide known to preserve the function of follicular melanocytes and is reported to be used as an ingredient in cosmetics [1].

MEDI-570 is a humanized IgG1 monoclonal antibody produced in CHO cells, targeting the inducible T-cell costimulator (ICOS/CD278). Functioning as a potent agonist, it binds with high affinity to the ICOS receptor, mimicking and amplifying the costimulatory signal of its natural ligand, ICOS-L. This agonistic activity promotes the activation, proliferation, survival, and cytokine production of T cells, including effector T cells and T follicular helper (Tfh) cells. It is developed as a cancer immunotherapeutic agent designed to combat tumors by enhancing T-cell function.

BVX20 is a human monoclonal antibody that binds to CD20. It can eliminate B cells by engaging the immune system. BVX20 is applicable in the study of relapsed or chemotherapy-resistant follicular B-cell non-Hodgkin lymphoma (NHL), as well as CD20-positive diffuse large B-cell non-Hodgkin lymphoma (NHL).

Propylparaben-d7 (Propyl parahydroxybenzoate-d7) is a deuterium-labeled form of Propylparaben. This compound serves as an antimicrobial preservative and is naturally produced by plants and bacteria. Propylparaben is extensively utilized in cosmetics, pharmaceuticals, and food products. It disrupts follicular development and steroidogenesis by altering the cell cycle, apoptosis, and steroidogenic pathways. Additionally, Propylparaben reduces sperm count and motility in rats.

Lecirelin is a synthetic GnRH (gonadotropin releasing hormone) analogue which shows a great efficacy in the treatment of bovine ovarian follicular cysts.

Lecirelin acetate is a synthetic GnRH (gonadotropin releasing hormone) analogue which shows a great efficacy in the treatment of bovine ovarian follicular cysts.

CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) with MMAE, targeting folate receptor (FRα) and TRPV6. It exhibits high binding affinity to FRα and low affinity to TRPV6. CBP-1008 shows antitumor activity and can be utilized for research in advanced solid tumors such as colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma, and follicular dendritic cell sarcoma.